StockNews.AI

Regulatory Setback For Applied Therapeutics' Lead Program, FDA Highlights Deficiencies In Clinical Application

Benzinga · 598 days

SORD
High Materiality8/10

AI Summary

FDA issued a Complete Response Letter for APLT's govorestat NDA. Deficiencies in clinical application cited, delaying potential approval and launch. William Blair downgraded success probability for galactosemia to 30%. SORD program remains unaffected; potential revenue by late 2025 possible. APLT stock dropped 67.2% following the FDA's decision.

Sentiment Rationale

The CRL significantly impairs approval timeline, similar past reactions saw deeper declines.

Trading Thesis

Approval delays may affect long-term revenue projections, akin to other biotech cases.

Market-Moving

  • FDA issued a Complete Response Letter for APLT's govorestat NDA.
  • Deficiencies in clinical application cited, delaying potential approval and launch.
  • William Blair downgraded success probability for galactosemia to 30%.

Key Facts

  • FDA issued a Complete Response Letter for APLT's govorestat NDA.
  • Deficiencies in clinical application cited, delaying potential approval and launch.
  • William Blair downgraded success probability for galactosemia to 30%.
  • SORD program remains unaffected; potential revenue by late 2025 possible.
  • APLT stock dropped 67.2% following the FDA's decision.

Companies Mentioned

  • SORD (SORD)

Others

Article outlines a critical setback which directly impacts APLT's viability and investor perception.

Related News